Swati G Patel1,2, Dennis J Ahnen3,4. 1. Department of Medicine, Division of Gastroenterology & Hepatology, University of Colorado Anschutz Medical Campus, 12631 East 17th Avenue, Campus Box 158, Aurora, Colorado, 80045, USA. Swati.Patel@ucdenver.edu. 2. Veterans Affairs Hospital, Denver, Colorado, USA. Swati.Patel@ucdenver.edu. 3. Department of Medicine, Division of Gastroenterology & Hepatology, University of Colorado Anschutz Medical Campus, 12631 East 17th Avenue, Campus Box 158, Aurora, Colorado, 80045, USA. 4. Gastroenterology of the Rockies, Boulder, Colorado, USA.
Abstract
PURPOSE OF REVIEW: Colorectal cancer incidence has been rapidly rising in those under the age of 50 over the last 20 years. This paper will review the epidemiology, clinicopathologic, molecular features, proposed risk factors, and prevention/treatment approach for early onset CRC (EOCRC) patients. RECENT FINDINGS: EOCRC appears to have a different spectrum of clinical, pathologic, and molecular presentation compared to CRC diagnosed in older individuals. EOCRCs are disproportionately located in the distal colon; these patients tend to present with symptoms, and there is a longer interval between symptoms and diagnosis. There may be a distinct molecular signature, including progression through the microsatellite and chromosomal stable (MACS) pathway and LINE-1 hypomethylation for a subset of EOCRCs. The majority of EOCRCs are sporadic without clear risk factors that would have made the patient eligible for earlier screening. There is an acute need for educational efforts aimed at both providers and patients to raise awareness about CRC in the young. Improving adherence to screening in young patients eligible for screening and emphasizing early evaluation of symptoms are important steps to decreasing the burden of CRC in younger patients. Modeling and empiric data are needed to determine whether our current screening approach should be modified and whether causation and treatment options may be different in a molecular subset EOCRCs.
PURPOSE OF REVIEW: Colorectal cancer incidence has been rapidly rising in those under the age of 50 over the last 20 years. This paper will review the epidemiology, clinicopathologic, molecular features, proposed risk factors, and prevention/treatment approach for early onset CRC (EOCRC) patients. RECENT FINDINGS: EOCRC appears to have a different spectrum of clinical, pathologic, and molecular presentation compared to CRC diagnosed in older individuals. EOCRCs are disproportionately located in the distal colon; these patients tend to present with symptoms, and there is a longer interval between symptoms and diagnosis. There may be a distinct molecular signature, including progression through the microsatellite and chromosomal stable (MACS) pathway and LINE-1 hypomethylation for a subset of EOCRCs. The majority of EOCRCs are sporadic without clear risk factors that would have made the patient eligible for earlier screening. There is an acute need for educational efforts aimed at both providers and patients to raise awareness about CRC in the young. Improving adherence to screening in young patients eligible for screening and emphasizing early evaluation of symptoms are important steps to decreasing the burden of CRC in younger patients. Modeling and empiric data are needed to determine whether our current screening approach should be modified and whether causation and treatment options may be different in a molecular subset EOCRCs.
Authors: R Gryfe; H Kim; E T Hsieh; M D Aronson; E J Holowaty; S B Bull; M Redston; S Gallinger Journal: N Engl J Med Date: 2000-01-13 Impact factor: 91.245
Authors: Hiroki Yuhara; Craig Steinmaus; Stephanie E Cohen; Douglas A Corley; Yoshihiro Tei; Patricia A Buffler Journal: Am J Gastroenterol Date: 2011-09-13 Impact factor: 10.864
Authors: José Perea; Yolanda Rodríguez; Daniel Rueda; José C Marín; José Díaz-Tasende; Edurne Álvaro; Cristina Alegre; Irene Osorio; Francisco Colina; Manuel Lomas; Manuel Hidalgo; Javier Benítez; Miguel Urioste Journal: Ann Surg Oncol Date: 2011-05-18 Impact factor: 5.344
Authors: C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava Journal: Cancer Res Date: 1998-11-15 Impact factor: 12.701
Authors: Kathryn L Lynch; Dennis J Ahnen; Tim Byers; David G Weiss; David A Lieberman Journal: Clin Gastroenterol Hepatol Date: 2003-03 Impact factor: 11.382
Authors: Zaid M Abdelsattar; Sandra L Wong; Scott E Regenbogen; Diana M Jomaa; Karin M Hardiman; Samantha Hendren Journal: Cancer Date: 2016-01-25 Impact factor: 6.860
Authors: Samir Gupta; Balambal Bharti; Dennis J Ahnen; Daniel D Buchanan; Iona C Cheng; Michelle Cotterchio; Jane C Figueiredo; Steven J Gallinger; Robert W Haile; Mark A Jenkins; Noralane M Lindor; Finlay A Macrae; Loïc Le Marchand; Polly A Newcomb; Stephen N Thibodeau; Aung Ko Win; Maria Elena Martinez Journal: Cancer Date: 2020-04-20 Impact factor: 6.860
Authors: Lorne J Hofseth; James R Hebert; Anindya Chanda; Hexin Chen; Bryan L Love; Maria M Pena; E Angela Murphy; Mathew Sajish; Amit Sheth; Phillip J Buckhaults; Franklin G Berger Journal: Nat Rev Gastroenterol Hepatol Date: 2020-02-21 Impact factor: 46.802
Authors: Rachel M Lee; Adriana C Gamboa; Michael K Turgeon; Mohammad Y Zaidi; Charles Kimbrough; Jennifer Leiting; Travis Grotz; Andrew J Lee; Keith Fournier; Benjamin Powers; Sean Dineen; Joel M Baumgartner; Jula Veerapong; Harveshp Mogal; Callisia Clarke; Gregory Wilson; Sameer Patel; Ryan Hendrix; Laura Lambert; Courtney Pokrzywa; Daniel E Abbott; Christopher J LaRocca; Mustafa Raoof; Jonathan Greer; Fabian M Johnston; Charles A Staley; Jordan M Cloyd; Shishir K Maithel; Maria C Russell Journal: J Surg Oncol Date: 2020-10-01 Impact factor: 3.454